Overall survival and histology‐specific subgroup analyses from a phase 3, randomized controlled study of trabectedin or dacarbazine in patients with advanced liposarcoma or leiomyosarcoma

Shreyaskumar Patel,Margaret von Mehren,Damon R. Reed,Pamela E. Kaiser,John A. Charlson,Christopher W. Ryan,Daniel A. Rushing,Michael B. Livingston,Arun S. Singh,Rahul Seth,Charles Forscher,Gina D'Amato,Sant P. Chawla,Sharon Anne McCarthy,George Wang,Trilok V. Parekh,Roland Elmar Knoblauch,Martee L. Hensley,Robert G. Maki,George D. Demetri

Overall survival and histology‐specific subgroup analyses from a phase 3, randomized controlled study of trabectedin or dacarbazine in patients with advanced liposarcoma or leiomyosarcoma

2019

Background We performed a randomized phase 3 study of trabectedin versus dacarbazine in previously‐treated patients with liposarcoma/leiomyosarcoma (LPS/LMS).

Keywords:

Pathology
Liposarcoma
Trabectedin
Randomized controlled trial
Leiomyosarcoma
Internal medicine
Oncology
Soft tissue sarcoma
Medicine
Histology
Dacarbazine
Phases of clinical research
Interim analysis
Sarcoma
Chemotherapy

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations